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ABSTRACT
Chronic graft-versus-host disease (cGVHD) is a serious and potentially life-threatening complication of
hematopoietic stem cell transplantation. This study, which is the largest single-center series of oral disease in
pediatric patients with cGVHD, describes the oral findings in 49 consecutive patients seen in a pediatric
multidisciplinary cGVHD clinic. All consecutive patients seen at the multidisciplinary pediatric hematopoietic
stem cell transplantation/cGVHD clinic at the Dana-Farber Cancer Institute (Boston, MA) from July 2001
through October 2003 were included in this study. Subjective and objective assessments of mucosal, salivary
gland, and sclerotic pathology were performed for each patient, and specific therapy was initiated when
indicated. Oral mucosal cGVHD was identified in 22 (45%) of 49 patients. Only 4 (8%) of 49 patients reported
mouth pain, and all patients reported being able to eat well. All patients who required specific therapy for their
oral mucosal cGVHD (45%) were already taking at least 1 immunomodulatory agent; however, efficacy of
treatment was difficult to assess because of inconsistent follow-up periods. Subjective and objective salivary
gland and sclerotic disease were observed far less often. Oral mucosal pathology is common in these patients,
and appropriate diagnosis and management of oral lesions is critical to reduce patient morbidity and to improve
quality of life. The apparent lack of salivary gland involvement was notable. Developing validated age-
appropriate evaluation strategies and identifying effective treatment guidelines will be invaluable in the future
management of these patients.
© 2005 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a
erious and potentially life-threatening complication
f hematopoietic stem cell transplantation (HSCT).
any patients with benign and malignant hemato-
ogic diseases now undergo HSCT. With continually
mproving survival rates, cGVHD has become one of
he leading long-term complications that causes both
orbidity and mortality in these patients [1].
The skin, liver, and gastrointestinal tract (includ-
ng the oral cavity) are the primary organs classically p
B&MTffected by cGVHD, although other systems may be
nvolved, such as the pulmonary system, depending on
he course and severity of disease. Oral involvement
rimarily affects the mucosa and salivary glands. Mu-
osal lesions are similar to those of oral lichen planus
nd are characterized by reticular, erythematous, or
lcerative involvement [2]. Sclerotic changes resulting
n trismus and reduced mobility of the stomatognathic
omplex may develop secondary to ﬁbrosis from
hronic and severe mucosal disease or may represent a
rimary process in the skin and muscles [3,4]. Salivary
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7land involvement is characterized by a decrease in
alivary gland output that potentially results in oral
iscomfort, an increased incidence of caries, candidi-
sis, and difﬁculties in eating, speaking, and swallow-
ng [5].
Although oral cGVHD has been characterized in
dult patients [6], the literature describing this condi-
ion in pediatric patients is scarce [7-12]. This study,
hich represents the largest single-center series of
ral disease in pediatric patients with cGVHD, de-
cribes the oral ﬁndings in 49 consecutive patients
een in a pediatric multidisciplinary cGVHD clinic.
ETHODS
All consecutive patients seen at the multidisci-
linary pediatric HSCT/cGVHD clinic at the Dana-
arber Cancer Institute (Boston, MA) from July 2001
hrough October 2003 were included in this study.
his is a long-term follow-up clinic that focuses on
atients with active issues, including but not limited to
GVHD. A standardized evaluation form designed by
he authors speciﬁcally for this clinic was completed
or every patient visit. A complete extraoral and in-
raoral clinical examination was performed for all pa-
ients, including subjective and objective assessments
f mucosal, salivary gland, and sclerodermatous pa-
hology. In addition, parents were permitted to assist
y encouraging the child and/or helping him or her
emember symptoms, and parental assessments were
sed as surrogates for children who were preverbal.
Oral mucosal cGVHD was classiﬁed as reticular
generally least symptomatic or asymptomatic), ery-
hematous (generally more symptomatic), or ulcer-
tive (generally most symptomatic), with lesions po-
entially described as having all 3 presentations. All
lcerative lesions were cultured for herpes simplex
irus. Pain and discomfort associated with mucosal
isease were assessed by using subjective questions.
ssessment of salivary gland involvement was based
n targeted questions and evaluation of saliva consis-
able 1. Pre-HSCT Diagnoses of Patients Included in the Study
n  49)
Diagnosis n
cute lymphoblastic leukemia 9
cute myelogenous leukemia 9
plastic anemia* 8
ongenital marrow failure syndrome 6
yelodysplasia 6
hronic myelogenous leukemia 3
ongenital immunodeficiency 3
emoglobinopathy 2
on-Hodgkins lymphoma 2
One of the patients with aplastic anemia was subsequently diag-
nosed as having dyskeratosis congenita and has been reportedaseparately [15].
22ency, mucosal dryness, presence or absence of ﬂoor-
f-mouth pooling, and the modiﬁed Schirmer test
13]. Sclerotic disease was assessed clinically and
hrough subjective questions. Other oral lesions were
ocumented primarily by clinical examination, although
histologic diagnosis was obtained when excision was
ndicated or the diagnosis was unclear. Select cases were
hotographed after receiving permission from the pa-
ients and their parents or guardians. When necessary,
peciﬁc therapy for the management of oral lesions was
nitiated. Institutional review board approval was ob-
ained for retrospective review of charts and the
SCT database of all of the patients included in this
tudy.
ESULTS
eneral Findings
Forty-nine patients who had been treated with
SCT for a variety of conditions were examined from
uly 2001 through October 2003 (Tables 1 and 2).
he age at the ﬁrst visit, age at transplantation, sex
istribution, time elapsed since transplantation, aver-
ge number of medications (immunomodulatory
rugs or drugs to treat symptoms related to cGVHD),
resence of oral cGVHD, salivary gland involvement,
able 2. Conditioning and Acute GVHD Prophylaxis Regimens for
atients before HSCT
Treatment No. Patients
onditioning regimen
CY, TBI 28
CY, ATG, TBI 5
CY, BU 3
CY, BU, FL, PRD 2
CY, Ara-C 1
CY, ATG 1
CY, VP-16 1
CY, BU, FL 1
CY, topotecan, TBI 1
CY, Ara-C, TBI 1
CY, ATG, procarbazine 1
BU, ATG, melphalan 1
CY, Ara-C, VP-16, TBI 1
cute GVHD prophylaxis
CSA, MTX, PRD 25
CSA, MTX 15
CSA 2
MTX 2
Tacrolimus, PRD 1
MTX, PRD 1
CSA, leucovorin, MTX, PRD 1
CSA, tacrolimus, MTX, PRD 1
everal patients underwent more than 1 transplantation (included in
the table) and there were incomplete data for 2 patients.
Y indicates cyclophosphamide; TBI, total body irradiation; VP-
16, etoposide; ATG, antithymocyte globulin; BU, busulfan; FL,
ﬂudarabine; PRD, prednisone/methylprednisolone; Ara-C, cy-
tosine arabinoside; CSA, cyclosporine; MTX, methotrexate.nd oral lesions requiring treatment are summarized
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Oral Chronic GVHD in Pediatric Patients after HSCT
Bn Table 3. There were 71 patient visits; most patients
67%) were evaluated only once (Figure 1). A history
f skin, gastrointestinal, or liver cGVHD involvement
as present in most patients (Table 4). Most patients
59%) were taking 1 or more of the following immu-
omodulatory medications: prednisone, cyclosporine,
ycophenolate mofetil, tacrolimus, sirolimus, hy-
able 3. Descriptive Statistics for All Patients
Variable Data
o. patients
49 (male, n  29;
female, n  20)
atient visits 71
edian no. visits (range) 1 (1-4)
ge at first visit, median (range) 11 (2-22)
ge at transplantation, y, median
(range) 8.5 (1-20)
ime since transplantation, y,
median (range) 2 (0.3-9)
o. medications,* median (range) 3 (0-21)
atients with oral mucosal cGVHD† 22/49 (45%)
atients requiring specific
treatment for oral mucosal
cGVHD 10/22 (45%)
atients with salivary gland
hypofunction‡ 2/49 (4%)
atients requiring treatment of oral
lesions§ 22/49 (45%)
Includes all medications (eg, topical, systemic, prescription, and
nonprescription); calculated as the greatest number of medica-
tions at any visit if the patient was seen more than once.
Oral mucosal cGVHD was considered present if lesions were
identiﬁed at any visit if the patient was seen more than once.
Salivary gland involvement was not assessed by minor salivary
gland biopsy or sialometry and may be affected by certain
medications.
This includes treatment of any oral lesions (eg, soft tissue hyper-
plasia), including but not limited to oral mucosal cGVHD.Figure 1. Number of visits (n  71) and number of p
B&MTroxychloroquine, azathioprine, or intravenous im-
unoglobulin. Only 9 patients were receiving pro-
hylactic antifungal medications (ﬂuconazole or
ystatin), 5 patients were receiving prophylactic anti-
iral medications (acyclovir, valacyclovir, or famciclo-
ir), and 27 patients were receiving prophylactic anti-
iotics (trimethoprim/sulfamethoxazole, amoxicillin,
enicillin, or cephalexin).
ubjective Findings
Subjective data pertaining to mucosal disease, sal-
vary gland function, presence of ﬁbrosis, and changes
n taste are detailed in Table 5. Whereas only 4 pa-
ients (8%) out of 49 reported mouth pain and all
atients reported being able to eat well, 10 patients
20%) admitted to avoiding certain foods because they
urt their mouths. Spicy and acidic foods and drinks
ere commonly cited irritants. Five patients (10%)
eported that their mouths were dry, although no
atient complained of difﬁculty swallowing. Four pa-
ients reported that their mouth or tongue felt tight.
nly 1 of these patients upon examination actually
able 4. History of cGVHD of the Skin, Liver, and Gastrointestinal
ract
Organ Involved
No. Patients
(n  49) %
kin 32 65
astrointestinal tract 31 63
iver 18 37
ther 9 18
one 7 14
ndividual patients may have had multiple visits and variable in-
volvement over time. Other was deﬁned as involvement of other
sites with cGVHD (eg, eyes, lungs, or joints).atients with oral cGVHD for the 49 patients.
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7ad clinical signs of soft tissue ﬁbrosis with limited
obility, as evidenced by obvious restricted mobility
f the tongue and labial mucosa (Figure 2). Regarding
hanges in taste perception before and after transplan-
ation, only 5 patients out of 49 reported that certain
oods tasted different after HSCT. It is interesting to
ote that these sensory changes were not uniformly
ositive or negative, but rather were described over-
helmingly as “different” for various foods.
bjective Findings
Oral mucosal cGVHD was identiﬁed in 22 (45%)
f 49 patients (Table 6). Most (42%) lesions were
rythematous, followed by reticular (36%) and ulcer-
tive (21%) forms. Eight of 22 patients (36% of pa-
ients with oral mucosal cGVHD) presented simulta-
able 5. Subjective Data
Question
Percentage
Responding
“Yes”
ucosal disease
Does your mouth hurt? 13%
Do you avoid any foods because they
make your mouth hurt? 23%
clerodermatous changes
Does your mouth or tongue feel tight? 8%
alivary gland involvement
Does your mouth feel dry? 13%
Can you swallow food without difficulty? 100%
aste
Does food taste the same now as it did
before transplantation? 90%
here were 5 instances in which the answers changed from one visit
to the next in patients who were seen more than once. In most
of these cases, the changes in subjective responses reﬂected
changes in their objective ﬁndings as well. For those who re-
sponded “no” to the taste question, the changes in taste were not
uniform and were often very speciﬁc to one or two foods.
igure 2. Soft tissue ﬁbrosis of the tongue resulting in restricted
obility. The tissue appeared pale and was somewhat ﬁrm to
alpation. e
24eously with a combination of 2 or more forms of
ucosal disease: reticular, erythematous, or ulcerative
Figure 3). Of the patients who were seen more than
nce (n  17), 6 (35%) were found to have different
orms of mucosal cGVHD at subsequent visits. This is
ndicative of the dynamic nature of this condition.
There were only 2 cases of putative salivary gland
able 6. Oral Mucosal cGVHD Lesions
Type
No. Patients
Affected %
eticular 12 36
rythematous 14 42
lcerative 7 21
otal 33 100
atients could have more than 1 lesion per visit, and each lesion
could have reticular, erythematous, and/or ulcerative compo-
nents. For example, a patient who was seen twice, with reticu-
lation of the right and left buccal mucosa and tongue dorsum
with a single ulcer on the right lateral tongue, would be counted
once for both reticular and ulcerative. Eight patients presented
with 2 or more forms, 5 patients presented with different forms
at different visits, and 1 patient ﬁrst presented with no mucosal
disease then subsequently developed reticulation.
igure 3. Oral mucosal cGVHD. A, Extensive reticulation of the
ongue dorsum. B, In a different patient, a solitary ulcerative lesion
f the right lateral tongue with associated erythema and reticulation
xtending posteriorly.
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BGVHD. In the ﬁrst case, the patient had both sub-
ective complaints of oral dryness and objective ﬁnd-
ngs of minimal salivary ﬂow and dryness, as evidenced
y an absence of ﬂoor-of-mouth pooling and gener-
lized dry, atrophic, and pale mucosa. In the second
ase, there were no subjective complaints, but objec-
ively there was minimal resting salivary ﬂow and
ryness, and there were rampant caries. The modiﬁed
chirmer test [13] was initially included as part of the
alivary function assessment, but it was discontinued
ecause of abundant salivary ﬂow in nearly all patients
15 mm at 1 minute in the ﬁrst 10 patients evaluated;
ata not shown), as well as difﬁculties in performing
he test accurately in very young children.
The most frequently encountered lesions other
han mucosal (reticular, erythematous, and ulcerative)
GVHD were atrophic glossitis (Figure 4A, B, and C),
ross caries, and soft tissue ﬁbrosis presenting as ei-
her limited opening due to sclerosis (Figure 5) of the
acial skin or limited mobility of soft tissue structures
Table 7). The patient with ﬁbrosis and limitation in
pening had undergone transplantation 2 years previ-
igure 4. Atrophic glossitis in the setting of cGVHD. A, Smooth an
, Distinct well-deﬁned area of partially depapillated tongue dorsu
ppearing as small islands of normal papillation. The border of an u
e seen.usly. No ulcerative lesions were culture positive for s
B&MTerpes simplex virus regardless of the presence or
bsence of prophylactic antiviral medications, and
nly 2 infectious lesions were identiﬁed. Both were
resentations of pseudomembranous candidiasis (Fig-
re 6), angular cheilitis, or both. One was in an indi-
illated tongue dorsum: unaffected areas appear completely normal.
Generalized atrophy of the tongue dorsum with unaffected areas
ve lesion extending from the ventral aspect of the right tongue can
igure 5. Sclerotic cGVHD of the lips and facial skin, mucosa, or
oth, resulting in marked limited opening of the mouth. This is thed depap
m. C,
lceratiame patient seen in Figure 3A.
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7idual who was not taking nystatin, and one was in
nother who was, although nystatin compliance was
ifﬁcult to ascertain.
Other lesions were noted in smaller numbers of
atients. Mucoceles were noted in 2 individuals. One
esion was in the lower labial mucosa, and the other
onsisted of several superﬁcial lesions on the palate
able 7. Other Oral Lesions Identiﬁed Clinically or Histologically
Variable n
ther primary lesions
Atrophic glossitis 9
Sclerosis/band formation 3
Commissural plaques* 3
Postinflammatory hyperpigmentation† 2
econdary lesions
Candidiasis/angular cheilitis‡ 2
Mucoceles (single or multiple) 2
Soft tissue hyperplasia§ 2
Coated tongue 1
Verruciform xanthoma 1
ncidental lesions
Gross caries 4
Papilloma/condyloma 2
Bite injury 2
Fibroma 1
Parulis 1
Other primary lesions” were deﬁned as being attributed directly to
cGVHD; “secondary lesions,” to treatment and immunosup-
pression; and “incidental lesions” were not considered to be
associated with cGVHD, HSCT, or treatment.
These white, plaquelike lesions resembled leukoplakias clinically.
However, histopathologic evaluation of identically appearing
lesions in adults was consistent with cGVHD (data not shown).
Pigmented lesions in the location of a cGVHD mucosal lesion
were assumed to be postinﬂammatory pigmentation.
One of these patients was taking nystatin, and neither was taking
topical steroids intraorally.
In one patient, soft tissue hyperplasia lesions of the buccal mucosa
and tongue were removed surgically and completely recurred
(Figure 8). In this case, this was counted only once.
igure 6. Pseudomembranous candidiasis of the left ventral tongue
hat easily wiped away with gauze, revealing an erythematous base. x
26Figure 7). A papillary tongue lesion in an 11-year-old
frican American girl appeared clinically to be a squa-
ous papilloma, but it was diagnosed histopatholog-
cally as a verruciform xanthoma (Figure 8). In an-
ther case, extensive soft tissue hyperplasia of the
uccal mucosa and lateral tongue bilaterally was noted
nd hypothesized to be associated with tacrolimus use
14]. It was surgically excised in the operating room
nder general anesthesia (Figure 9). After a rapid
ecurrence, the lesions were excised a second time 6
eeks after the ﬁrst operation, and tacrolimus use was
inimized. Since the second excision, the lesions have
ot recurred at nearly 2 years of follow-up. Another
atient presented with a tongue leukoplakia that was
iagnosed histopathologically as dysplasia; this pa-
ient, reported previously, initially underwent trans-
lantation for aplastic anemia, but the ultimate diag-
osis was dyskeratosis congenita [15].
reatment
Any patient with gross caries was advised to see a
entist as soon as possible. Incisional biopsy was rec-
Figure 7. Superﬁcial mucocele of the soft palate.
igure 8. Exophytic papillary pink lesion of the right posterior
ateral tongue that was histopathologically diagnosed as verruciform
anthoma.
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Bmmended for all leukoplakias, and excisional biopsy
as recommended for all soft tissue nodules or masses.
reatment of oral mucosal cGVHD was initiated with
uocinonide or clobetasol 0.05% gel, tacrolimus 0.1%
intment, dexamethasone elixir (0.5 mg/5 mL), and
ntralesional triamcinolone (40 mg/mL) injections
sed singly or in combination. All patients who re-
uired speciﬁc therapy for their oral mucosal cGVHD
45%) were already taking at least 1 immunomodula-
ory agent (except for 1 patient who was taking only
rimethoprim/sulfamethoxazole). Response to therapy
as difﬁcult to assess because of inconsistent follow-
p, different lengths of time between visits, and vari-
tions in doses of systemic immune suppression. Both
ases of putative salivary gland cGVHD were treated
onservatively with home ﬂuoride applications and
ncreased hydration. In the second case, the patient
as also referred to an oral surgeon for extractions of
onrestorable carious teeth. Only 1 mucocele was
ecommended for excision because it had been present
or several months and was located deep in the labial
ucosa. The cases of candidiasis responded to either
ystatin or ﬂuconazole treatment.
ISCUSSION
Graft-versus-host disease (GVHD) is classiﬁed as
ither acute or chronic. Acute GVHD occurs within
he ﬁrst 100 days after allogeneic HSCT, and
GVHD occurs thereafter. The clinical manifesta-
ions of cGVHD are similar to those of a wide range
f autoimmune diseases, such as Sjögren syndrome
nd systemic sclerosis [16,17]. Tissue damage seems to
e mediated largely by activated donor T cells that
ecognize host antigens as foreign and attack target
rgans such as the skin, liver, and gastrointestinal tract
igure 9. Extensive lobulated tissue hyperplasia of the tongue,
utatively associated with use of tacrolimus. There was also an
nderlying atrophic glossitis.16]. Chronic GVHD is associated with signiﬁcant c
B&MTmmunodeﬁciency due to impaired T- and B-cell pro-
uction and function that is further exacerbated by
reatment with immunosuppressant medications
5,16]. In patients undergoing HSCT from matched
elated donors, the incidence of cGVHD (in those
ho survive HSCT) has been reported as 13% in
atients younger than 10 years, 28% in patients 10 to
9 years, and 40% in patients older than 20 years
18]. The overall numbers after matched unrelated
onor HSCT are signiﬁcantly higher [19]. Risk fac-
ors for cGVHD in the pediatric population include
iagnosis, donor and recipient age, female donor for
ale recipient, history of acute GVHD, and use of
otal body irradiation, although none is speciﬁc for
ral involvement [20]. Overall, cGVHD is estimated
o affect 50% of surviving adults and 20% of surviving
hildren [12]. Approximately one half of affected pa-
ients have limited involvement. Of patients with
ore extensive disease, approximately 60% respond
ell to immunosuppressive therapy. However, the
ther 40% require prolonged immunosuppressive
herapy and may die from opportunistic infections or
dvanced organ involvement [5].
In this study, we report the oral ﬁndings from 49
hildren who underwent HSCT for a variety of be-
ign and malignant disorders and who were seen in a
ong-term follow-up clinic that specialized in evaluat-
ng patients with cGVHD. Accordingly, approxi-
ately 90% of patients had a history of any cGVHD.
lmost 50% were found to have oral cGVHD. De-
pite systemic management of cGVHD, 10 patients
equired additional topical and/or intralesional treat-
ent speciﬁcally directed toward their oral mucosal
esions (predominately erythematous and ulcerative
orms).
To date, only 3 large-scale studies have described
he oral ﬁndings in pediatric patients with cGVHD
fter HSCT (Table 8) [7-9,12]. Comparing our results
ith the ﬁndings of these studies is difﬁcult because of
ifferences in demographics, genetic disparities, con-
itioning regimens, cell sources, transplantation and
VHD prophylaxis protocols, study design, length of
ollow-up, and techniques, criteria, and terminology
or evaluating oral involvement. In the prior reports,
pproximately 20% of patients were found to have
ral cGVHD. In this study, 45% of subjects were
ffected. This is likely due to selection bias. We were
ore likely to see patients with more extensive disease
ecause this follow-up clinic favored scheduling of
atients with known or suspected HSCT-related com-
lications. Our distribution of reticular, erythematous,
nd ulcerative lesions was more or less consistent with
revious ﬁndings (to the extent that these classiﬁca-
ions were used in prior reports), although we seemed
o have a slightly higher proportion of ulcerative le-
ions. This classiﬁcation of lesions is important be-
ause reticular lesions rarely require intervention,
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Table 8. Previous Reports of Pediatric Oral cGVHD in Large-scale Studies
Study No. of Patients
Patients with Oral
cGVHD % M/F Age, y (range)
Time Since
Transplantation Method of Evaluation Findings Treatments
Berkowitz et al.
(1987) [7]
41
(prospective
study;
patients
observed
before
HSCT)
8/41 (20%) 63% M
37% F
9.3 (7 mo to
7 y)
Not specified Mucosal disease assessed
by clinical and
histologic examination
Salivary gland
hypofunction assessed
clinically
Lichenoid: 1/8
Erythema: 7/8
Xerostomia: 4/8
Hyposalivation resolved in
2/4 patients within 6 mo
and persisted in 2/4 for
1 y; however, none
developed caries
Anesthetic mouth rinse,
systemic steroids,
saliva substitutes,
topical fluoride
Dahllof et al. (1988,
1989) [8, 9]
54
(prospective
study; all
patients
observed
before
HSCT)
9/45 (20%) patients
observed for >6
mo. Three
patients died
within the first
year; 6 were long-
term survivors
57% M
43% F
7 (1-12) 6 mo to 7 y
(median,
3.9 y)
Mucosal disease assessed
by clinical and
histologic examination
Salivary gland
hypofunction assessed
by sialometry
Skin and oral involvement
in all cases
Of the 6 long-term
survivors:
Up to 1 y after HSCT:
Erythema: 3/6
Erosive lichenoid: 2/6
Atrophic lichenoid: 1/6
Beyond 1 y after HSCT:
Atrophic lichenoid: 5/6
Erythema: 1/6
Average salivary flow rate
1 y after HSCT was
0.7 mL/min.
Average salivary flow rate
after the first year
was 1.1 mL/min
Sugar-free chewing
gum, fluoride varnish,
treatment of mucosal
disease not specified
Nicolatou-Galitis et al.
(2001) [12]
90 patients
were
screened for
evidence of
cGVHD; 11
were
included in
the study
8/11 (73%) or 8/90
(9%)
73% M
27% F
10.7 (1.5-15) 172 d (range,
81-360)
Mucosal disease assessed
by clinical and
histologic examination
Salivary gland
hypofunction assessed
clinically
Lichenoid: 4/8
Ulcerative: 2/8
Hyposalivation: 7/8
Mucoceles: 3/8
Systemic and topical
steroids, cyclosporin A
N
.S.T
reister
et
al.
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Bhereas erythematous and ulcerative lesions typically
emand aggressive therapy.
The prevalence of sclerotic oral cGVHD (clini-
ally) seemed very low. This is consistent with the
ndings of others that sclerotic cGVHD is rare and
ends to occur as a late event [21]. The apparent lack
f salivary gland involvement—only 5 patients com-
lained of xerostomia (subjective oral dryness), and
nly 2 (4%) patients had any clinical evidence of
yposalivation (by visual assessment)—was notable,
specially because this was a designated cGVHD
linic. Nicolatou-Galitis et al. [12] reported 7 of 8
atients with cGVHD (in part diagnosed by minor
alivary gland biopsy) and clinically obvious xerosto-
ia; this is a much higher percentage than observed in
ur study. However, there was no description of how
erostomia or hyposalivation was assessed in the
forementioned study, so it is unclear to what extent
ur ﬁndings are signiﬁcantly different. Our ﬁndings
lso seem to be in contrast to those in the adult
opulation with cGVHD, in which salivary gland in-
olvement is reported to be much more prevalent,
ith approximately 60% developing xerostomia, 40%
o 90% demonstrating hyposecretion, and 0% to 50%
howing clinical signs of dryness [6,22,23]; this differ-
ntial involvement in the 2 populations warrants fur-
her investigation. Furthermore, improved under-
tanding of the relationship between objective and
ubjective measures of salivary gland involvement, es-
ecially with respect to age, is critical in this patient
opulation.
Mucoceles were reported infrequently by Nicola-
ou-Galitis et al. [12], and we similarly found only 2
atients with mucoceles. Mucoceles in these patients
ay be attributable to low-level cGVHD of the sali-
ary gland acini and ducts (causing increased viscosity,
ecreased ﬂow, and weakening and/or leakiness of the
uctal epithelium) or to local extension and involve-
ent of mucosal cGVHD into underlying salivary
ucts [24,25]. We did not observe clinically evident
alivary gland or local (ie, in the area of the mucocele)
ral mucosal cGVHD in our 2 patients; however, the
superﬁcial mucoceles observed by Nicolatou-Galitis
t al. were seen in the setting of mild to heavy salivary
land cGVHD (histologically) in 2 patients and prom-
nent lichenoid mucosal lesions in the other.
Diagnosis of oral symptoms and ﬁndings in this
ediatric patient population is frequently a more com-
lex undertaking than in adults, because procedures
uch as biopsies (and, in some cases, even clinical
xamination) present unique challenges. For example,
t is not entirely possible to rule out candidiasis in the
ifferential diagnosis of erythematous cGVHD lesions
linically (although they can be easily cultured if can-
idiasis is suspected). However, no cases of assumed
rythematous cGVHD worsened with topical steroid
reatment (in most cases, this follow-up was assessed c
B&MTy the transplant specialists and not the oral medicine
pecialists), thus suggesting that treatment on the basis
f clinical ﬁndings alone is reasonable in this popula-
ion. The young age of the patient population also
nﬂuenced the subjective assessment of xerostomia be-
ause it was not clear whether all patients truly under-
tood what the question (“Does your mouth feel
ry?”) meant. However, the failure of patients (or
heir parental surrogates) to report difﬁculty with eat-
ng and swallowing food (which is a more common
omplaint in the adult population [6]) supports the
nference that the prevalence of putative salivary gland
ypofunction was very low in this population. Fur-
hermore, it is possible that some positive responses to
he targeted subjective questions regarding oral tight-
ess reﬂected the sensation of facial fullness related to
ong-term prednisone treatment rather than actual
issue ﬁbrosis. It is not yet clear what the most reliable
valuation should consist of for the youngest patients.
Oral evaluations contributed to the establishment
f systemic diagnoses [15] and also resulted in recog-
ition of novel pathologies other than oral cGVHD.
he diagnosis for the patient with dyskeratosis con-
enita was in part based on the oral ﬁndings of leu-
oplakia rather than cGVHD and tongue biopsy. Al-
hough a single case of verruciform xanthoma has
een reported in the young adult cGVHD population
26], it is exceedingly rare in children and has never
een reported in the pediatric cGVHD population.
he precise etiology of the soft tissue hyperplasia in
he patient taking tacrolimus is unclear [27]. However,
imilar lesions have been reported to occur in patients
aking cyclosporine (another calcineurin inhibitor).
ur case suggests that this complication may be seen
ith other members of this class of drug and thereby
uggests that the shared mechanism of action may be
elated to the development of these lesions. A rela-
ionship to the drug is suggested by the nearly com-
lete recurrence after the ﬁrst excision, followed by
esolution when the drug dose was minimized after
he second excision.
Thus, careful oral examination is likely to make
igniﬁcant contributions to understanding and man-
ging the increasing number of children who survive
SCT. Oral mucosal pathology is common in these
atients, and appropriate diagnosis and management
f oral lesions is critical to reduce patient morbidity
nd to improve quality of life. Although efﬁcacy could
ot be determined with certainty, patients seemed to
eneﬁt from treatment regimens; however, future
tudies are needed to establish optimal approaches.
ge-related issues such as the ease and acceptability of
iopsy and the reliability and availability of self-assess-
ent of subjective symptoms need to be considered in
he development of evaluation and treatment strate-
ies. This cross-sectional analysis suggests that
GVHD ﬁndings are similar to those seen in adults,
729
a
t
u
v
o
t
a
o
w
m
a
t
m
t
t
e
e
g
e
m
h
m
l
t
c
g
c
r
A
F
t
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
N. S. Treister et al.
7lthough hyposalivation is not a common complica-
ion in these younger patients. The absence of severe
lcerative oral mucosal cGVHD and, apparently, a
ery low prevalence of oral pain (both of which are
ften seen in the adult population) further emphasize
he importance of describing and investigating the
pparent age-related differences in the presentation of
ral cGVHD.
Identifying treatment strategies for this condition
ill be an invaluable advance in the effective manage-
ent of these patients. Development of validated age-
ppropriate evaluation strategies is critical. In addi-
ion, the study suggests that active participation of oral
edicine practitioners in the long-term follow-up of
hese patients is likely to signiﬁcantly affect not only
he proper management of oral cGVHD, but also the
stablishment of other diagnoses and treatment strat-
gies. For example, the observation of impaired dental
rowth and development that seems to be due to
ffects from HSCT conditioning regimens may have
ajor signiﬁcance for ongoing management of oral
ealth, including restorative and orthodontic treat-
ents [11]. Establishment of additional long-term fol-
ow-up data is paramount to guide clinicians in the
reatment of pediatric oral cGVHD and to minimize
omorbidities such as infection, impaired dental
rowth, and development of secondary oral malignan-
ies, which these patients may be at especially high
isk for developing [28,29].
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